Overview

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

Status:
Completed

Trial end date:
2020-07-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of TAK-659 when administered in combination with bendamustine, bendamustine + rituximab, gemcitabine, lenalidomide, or ibrutinib.

Phase:

Phase 1

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Treatments:

Bendamustine Hydrochloride
Gemcitabine
Lenalidomide
Rituximab
Thalidomide